Answers are grounded in this paper and cite their sources.
Uveal melanoma is a rare cancer, in which metastases occur in approximately one half of cases. In metastatic disease, the prognosis is unfavorable and the median of survival does not exceed 6 months. Effective treatment options were very limited up to date. Tebentafusp is a bispecific fusion protein, which as the first drug proved efficacy in uveal melanoma.
No takes yet. Share an insight, caveat, or question.
Klabusay et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: